The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer.
 
Takahiro Kogawa
No Relationships to Disclose
 
Kan Yonemori
Consulting or Advisory Role - Eisai; Novartis
Speakers' Bureau - Eisai; Mochida Pharmaceutical Co. Ltd.; Novartis; Taiho Pharmaceutical
 
Yoichi Naito
No Relationships to Disclose
 
Emi Noguchi
Consulting or Advisory Role - Chugai Pharma; Novartis
 
Chikako Shimizu
Consulting or Advisory Role - Pfizer
Research Funding - Chugai Pharma (Inst); Lilly Japan (Inst); Pfizer (Inst)
 
Kenji Tamura
No Relationships to Disclose
 
Ako Hosono
No Relationships to Disclose
 
Nobuaki Matsubara
No Relationships to Disclose
 
Masahiro Sugihara
Employment - Daiichi Sankyo
 
Hayao Ogawa
Employment - Daiichi Sankyo
 
Shuji Majima
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Channing Yu
Employment - Daiichi Sankyo
 
Suguru Ueno
Employment - Daiichi Sankyo
 
Toshimi Takano
Honoraria - Daiichi Sankyo; Eisai; Kyowa Hakko Kirin
Research Funding - Chugai Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Puma Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)